Abstract
Patients with early-stage nasopharyngeal cancer are treated with definitive radiotherapy alone, including both sides of the neck and retropharyngeal nodes. For patients with locoregionally advanced nasopharyngeal cancer, the recommendation is concurrent chemoradiotherapy with additional chemotherapy (either before or after chemoradiotherapy). Adding targeted therapies like nimotuzumab to concurrent chemoradiation in the management of nasopharyngeal cancer has been shown to improve overall survival with excellent safety and tolerability.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
